Cancer

Title
Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)
Trial Number
205185051513
Number of Participants
50
Principal Investigator

Scott Smith

M.D.,Ph.D., FACP
Hematology/Oncology
Associate Professor
Eligibility

Individuals eligible for this study must have a documented histopathological diagnosis of classical HL excluding nodular lymphocyte predominant HL (NLPHL); must have relapsed or refractory disease after failure of standard front-line chemotherapy for the treatment of classical Hodgkin lymphoma, must have bidimensional measurable disease; must be18 years or older; and must meet lab criteria.

Purpose

The purpose of this research study is to gather information about the effectiveness and safety of a drug called brentuximab vedotin when given in combination with another drug called bendamustine for Hodgkin lymphoma.

Enrollment

(708) 327-3228

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.